Advertisement

Topics

Transcatheter Aortic Valve Implantation TAVI Market by Procedure Transfemoral Implantation, Transapical Implantation, and Transaortic Implantation Global Opportunities and Forecasts, 20142022 [Report Updated: 05092016] Prices from USD $5370

11:35 EDT 11 Aug 2017 | BioPortfolio Reports

Transcatheter aortic valve implantation TAVI, also called as transcatheter aortic valve replacement TAVR, is a minimally invasive surgical procedure, wherein a diseased aortic valve is replaced with artificial valve through blood vessels. The procedure is designed to treat highrisk patients suffering from aortic stenosis. These highrisk patients refer to the patient population that are either inoperable or unfit to undergo surgical aortic valve replacement SAVR procedure. The older population above 75 years of age falls under the highrisk category, as the open heart surgery is too risky for them. TAVI involves implantation of transcatheter aortic valves to regenerate the blood circulation ability of the aortic valve.nnThe world TAVI market is driven by the rise in geriatric population that results in increase in prevalence of aortic stenosis, advancements in transcatheter aortic valves, and increase in adoption rate of TAVI devices. However, stringent and timeconsuming government regulations for transcatheter aortic valves being class III medical devices and their high cost are set to restrain the market growth.nnThe report segments the TAVI market on the basis of procedure and geography. According to procedure, the market is classified into transfemoral, transapical, and transaortic implantation. On the geographical basis, it is analyzed across North America, Europe, AsiaPacific, and LAMEA.nnThe TAVI market is highly competitive and consolidated in nature. Edwards Lifesciences Corporation, Medtronic plc, and St. Jude Medical, Inc. have dominated the overall market. These players have adopted product development as their key strategy, and hence launched several technologically advanced transcatheter aortic valves in the past few years. For instance, in March 2016, Direct Flow Medical, Inc. launched its nextgeneration DirecTrack TAVR delivery system in the European market. In the same year, Edwards Lifesciences Corporation received the Ministry of Health, Labour and Welfare MHLW approval for launch of its SAPIEN 3 transcatheter heart valve in the Japanese market. The market has also witnessed several approvals for clinical trials of transcatheter aortic valves. For instance, in June 2016, Medtronic plc received approval for its CoreValve Evolut R US Clinical Study.nnKey players profiled in this report are:nnnnBoston Scientific CorporationnnDirect Flow medical, Inc.nnEdwards Lifesciences Corporation,nnHLT, Inc., JenaValve Technology, Inc.nnMedtronic plcnnMeril Life Sciences Pvt. Ltd.nnSt. Jude Medical, Inc.nnSYMETIS SAnnTranscatheter Technologies GmbH.nnnKEY BENEFITS:nnnnThis report provides an extensive analysis of the current trends, future estimations, and dynamics in the world TAVI market through 2014ndash;2022, which assists to identify the prevailing opportunities.nnIndepth analysis is conducted by market estimations for the key segments for both value and volume.nnComprehensive analysis of factors that drive and restrict the growth of the TAVI market is provided.nnAn indepth analysis of current research and clinical developments within the market is presented.nnnKey market players are profiled and their strategies are analyzed thoroughly, which interprets the competitive outlook of the world TAVI market.nnKEY MARKET SEGMENTS:nnBy ProcedurennnnTransfemoral ImplantationnnTransapical ImplantationnnTransaortic ImplantationnnnBy GeographynnnnNorth AmericannnnnnU.S.nnnCanadannnMexiconnnnnnEuropennnnnGermanynnnFrancennnUKnnnItalynnnSwitzerlandnnnRest of EuropennnnnnAsiaPacificnnnnnChinannnJapannnnIndiannnRest of AsiaPacificnnnnnnLAMEAnnnnnBrazilnnnIsraelnnnSouth AfricannnSaudi ArabiannnRest of LAMEAnnnnn

Original Article: Transcatheter Aortic Valve Implantation TAVI Market by Procedure Transfemoral Implantation, Transapical Implantation, and Transaortic Implantation Global Opportunities and Forecasts, 20142022 [Report Updated: 05092016] Prices from USD $5370

NEXT ARTICLE

More From BioPortfolio on "Transcatheter Aortic Valve Implantation TAVI Market by Procedure Transfemoral Implantation, Transapical Implantation, and Transaortic Implantation Global Opportunities and Forecasts, 20142022 [Report Updated: 05092016] Prices from USD $5370"

Quick Search
Advertisement
 

Relevant Topic

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...